Commerzbank Aktiengesellschaft FI Buys 11,965 Shares of The Clorox Company $CLX

Commerzbank Aktiengesellschaft FI grew its stake in The Clorox Company (NYSE:CLX) by 564.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,085 shares of the company’s stock after acquiring an additional 11,965 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Clorox were worth $1,737,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in CLX. MBM Wealth Consultants LLC purchased a new position in Clorox in the third quarter valued at about $406,000. Mendel Capital Management LLC boosted its holdings in shares of Clorox by 8.9% in the 3rd quarter. Mendel Capital Management LLC now owns 4,246 shares of the company’s stock valued at $524,000 after buying an additional 346 shares in the last quarter. Blackhawk Capital Partners LLC bought a new stake in shares of Clorox in the 3rd quarter valued at about $1,350,000. UniSuper Management Pty Ltd grew its position in shares of Clorox by 2.9% in the 3rd quarter. UniSuper Management Pty Ltd now owns 77,206 shares of the company’s stock worth $9,520,000 after buying an additional 2,182 shares during the last quarter. Finally, TrueMark Investments LLC bought a new position in shares of Clorox during the 3rd quarter worth approximately $6,680,000. 78.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

CLX has been the subject of several recent analyst reports. Wells Fargo & Company raised their target price on shares of Clorox from $108.00 to $115.00 and gave the company an “equal weight” rating in a research note on Friday. Morgan Stanley lowered their price objective on Clorox from $137.00 to $125.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 4th. UBS Group dropped their target price on Clorox from $119.00 to $115.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 14th. Citigroup decreased their price target on Clorox from $120.00 to $109.00 and set a “neutral” rating for the company in a research note on Wednesday, December 17th. Finally, The Goldman Sachs Group lowered their price target on Clorox from $110.00 to $94.00 and set a “sell” rating for the company in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Buy rating, thirteen have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Clorox currently has an average rating of “Reduce” and a consensus price target of $122.19.

Insider Transactions at Clorox

In other Clorox news, Director Pierre R. Breber purchased 4,000 shares of the stock in a transaction on Friday, November 21st. The shares were bought at an average cost of $104.13 per share, with a total value of $416,520.00. Following the completion of the acquisition, the director owned 13,000 shares in the company, valued at $1,353,690. This trade represents a 44.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.63% of the stock is owned by corporate insiders.

More Clorox News

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Clorox agreed to acquire GOJO Industries, the maker of Purell, for $2.25 billion in cash — a strategic push deeper into skin health and hygiene that management says is growth‑accretive and advances its IGNITE plan. The deal expands Clorox’s consumer and professional hygiene footprint and is the primary catalyst for today’s stock strength. Clorox Announces Acquisition of GOJO
• Positive Sentiment: Management updated FY‑2026 EPS guidance to $5.95–$6.30, slightly above consensus, and reiterated revenue targets — a sign the company expects the combined portfolio and cost initiatives to help stabilize growth. This guidance helped reassure investors even as organic revenue pressures persist. (Company guidance release)
• Neutral Sentiment: Deutsche Bank raised its price target on CLX to $114 (keeps a Hold rating), a small incremental positive that signals modest upside in analysts’ view but not a strong buy signal. Deutsche Bank Raises Price Target
• Neutral Sentiment: Broad media and analyst coverage (WSJ, CNBC, MarketWatch) has amplified the deal’s reach and provided investors with deal details and management commentary — increasing attention but not resolving long‑term execution questions. WSJ: Clorox to Buy Purell-Maker
• Negative Sentiment: Some sell‑side skepticism remains: Barclays kept an Underweight (sell) stance despite a small target tweak, and commentary from critics highlights valuation and fundamental concerns that could limit upside until integration is proven. Barclays Remains a Sell
• Negative Sentiment: The deal is being financed with debt, increasing leverage and short‑term balance‑sheet risk; investors will watch integration execution and cost synergy realization closely — these risks are why some analysts remain cautious. WSJ: Deal Financed with Debt
• Negative Sentiment: Critical commentary (e.g., Seeking Alpha) questions whether the acquisition meaningfully fixes Clorox’s underlying growth challenges and suggests the company still needs stronger organic execution — a narrative that could cap the stock if results don’t improve. Seeking Alpha: Adding Sanitizers, But In Need Of Getting Its Hands Dirty

Clorox Trading Up 1.1%

Shares of NYSE:CLX opened at $113.46 on Monday. The company has a quick ratio of 0.50, a current ratio of 0.76 and a debt-to-equity ratio of 18.01. The Clorox Company has a 52-week low of $96.66 and a 52-week high of $164.22. The stock has a market cap of $13.84 billion, a price-to-earnings ratio of 17.81, a PEG ratio of 0.57 and a beta of 0.58. The business has a 50-day moving average price of $103.80 and a 200-day moving average price of $114.70.

Clorox (NYSE:CLX) last issued its earnings results on Monday, November 3rd. The company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.07. Clorox had a return on equity of 358.39% and a net margin of 11.68%.The firm had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.41 billion. During the same quarter in the prior year, the firm earned $1.86 earnings per share. Clorox’s revenue for the quarter was down 18.9% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. Equities analysts predict that The Clorox Company will post 7.15 EPS for the current year.

Clorox Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Wednesday, January 28th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 4.4%. The ex-dividend date of this dividend is Wednesday, January 28th. Clorox’s dividend payout ratio (DPR) is 77.86%.

Clorox Company Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.